PL3267984T4 - Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory - Google Patents
Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatoryInfo
- Publication number
- PL3267984T4 PL3267984T4 PL16761169T PL16761169T PL3267984T4 PL 3267984 T4 PL3267984 T4 PL 3267984T4 PL 16761169 T PL16761169 T PL 16761169T PL 16761169 T PL16761169 T PL 16761169T PL 3267984 T4 PL3267984 T4 PL 3267984T4
- Authority
- PL
- Poland
- Prior art keywords
- immunomodulators
- oxadiazol
- thiadiazol
- compounds
- thiadiazol compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1178CH2015 | 2015-03-10 | ||
| IN1180CH2015 | 2015-03-10 | ||
| EP16761169.8A EP3267984B1 (en) | 2015-03-10 | 2016-03-07 | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| PCT/IB2016/051266 WO2016142833A1 (en) | 2015-03-10 | 2016-03-07 | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3267984T4 true PL3267984T4 (pl) | 2022-05-02 |
| PL3267984T3 PL3267984T3 (pl) | 2022-05-02 |
Family
ID=56879282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16761169T PL3267984T3 (pl) | 2015-03-10 | 2016-03-07 | Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10781189B2 (enExample) |
| EP (2) | EP4023645A1 (enExample) |
| JP (5) | JP6815686B2 (enExample) |
| KR (2) | KR102708045B1 (enExample) |
| CN (4) | CN114159430B (enExample) |
| AU (3) | AU2016230793B2 (enExample) |
| CA (2) | CA2979137C (enExample) |
| CU (1) | CU24509B1 (enExample) |
| CY (1) | CY1125161T1 (enExample) |
| DK (1) | DK3267984T3 (enExample) |
| EA (1) | EA034708B1 (enExample) |
| ES (1) | ES2907988T3 (enExample) |
| HR (1) | HRP20220258T1 (enExample) |
| HU (1) | HUE058274T2 (enExample) |
| IL (3) | IL254040B2 (enExample) |
| LT (1) | LT3267984T (enExample) |
| MX (2) | MX389392B (enExample) |
| MY (1) | MY196130A (enExample) |
| NZ (1) | NZ734650A (enExample) |
| PH (1) | PH12017501454A1 (enExample) |
| PL (1) | PL3267984T3 (enExample) |
| PT (1) | PT3267984T (enExample) |
| RS (1) | RS62960B1 (enExample) |
| SG (2) | SG10202108921VA (enExample) |
| SI (1) | SI3267984T1 (enExample) |
| SM (1) | SMT202200163T1 (enExample) |
| WO (1) | WO2016142833A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201504410PA (en) | 2012-12-07 | 2015-07-30 | Chemocentryx Inc | Diazole lactams |
| EA030155B1 (ru) | 2013-09-06 | 2018-06-29 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,2,4-оксадиазола в качестве иммуномодуляторов |
| KR102708045B1 (ko) | 2015-03-10 | 2024-09-23 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| AU2017246460B2 (en) | 2016-04-07 | 2021-04-22 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
| WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| WO2018051254A1 (en) * | 2016-09-14 | 2018-03-22 | Aurigene Discovery Technologies Limited | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators |
| EP4234691A3 (en) | 2016-10-14 | 2023-10-18 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| EA201990997A1 (ru) * | 2016-10-20 | 2019-08-30 | Ориджин Дискавери Текнолоджиз Лимитед | Двойные ингибиторы vista и путей pd-1 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| CN108395443B (zh) * | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018196768A1 (zh) * | 2017-04-26 | 2018-11-01 | 南京圣和药业股份有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| CN109096219B (zh) * | 2017-06-20 | 2023-03-21 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| WO2019061324A1 (en) * | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| JP7618445B2 (ja) | 2017-10-11 | 2025-01-21 | オーリジーン オンコロジー リミテッド | ３－置換１，２，４－オキサジアゾールの結晶形態 |
| CN111372584A (zh) * | 2017-11-03 | 2020-07-03 | 奥瑞基尼探索技术有限公司 | Tim-3和pd-1途径的双重抑制剂 |
| EA202090749A1 (ru) * | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
| US20200353050A1 (en) | 2017-11-10 | 2020-11-12 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| EA202091267A1 (ru) * | 2018-01-12 | 2020-11-03 | Ориджен Дискавери Текнолоджис Лимитед | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| WO2019175799A2 (en) * | 2018-03-14 | 2019-09-19 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| CN108586549A (zh) * | 2018-05-31 | 2018-09-28 | 成都市科隆化学品有限公司 | 一种Fmoc-Thr(tBu)-OH的制备方法 |
| US20210347842A1 (en) | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN111057069B (zh) * | 2018-10-16 | 2024-01-26 | 武汉光谷通用名药物研究院有限公司 | 一种环状化合物、其应用及组合物 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020095256A1 (en) * | 2018-11-08 | 2020-05-14 | Aurigene Discovery Technologies Limited | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
| BR112021012103A2 (pt) | 2018-12-21 | 2021-09-08 | Aim Immunotech Inc. | Composições e métodos para terapia de câncer |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN111909108B (zh) * | 2019-09-02 | 2023-05-02 | 中国药科大学 | 联苯类化合物及其制备方法和医药用途 |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| EP4146345A2 (en) | 2020-05-05 | 2023-03-15 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| CA3204162A1 (en) | 2021-01-11 | 2022-07-14 | Robert Kastelein | Compositions and methods related to receptor pairing |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4370139A4 (en) | 2021-07-14 | 2025-10-15 | Synthekine Inc | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| EP4554943A1 (en) | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1557852A (en) * | 1922-08-15 | 1925-10-20 | Lauerman Clarence Haines | Galvanized-iron ventilator |
| US3227725A (en) | 1962-04-17 | 1966-01-04 | Union Carbide Corp | Certain 3,5-disubstituted 1,2,4-oxadiazole compounds |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| TW201311B (enExample) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| AU1739099A (en) * | 1994-03-08 | 1999-05-20 | American Home Products Corporation | Effector proteins of rapamycin |
| CA2143246C (en) * | 1994-03-16 | 2000-08-22 | Thierry Godel | Imidazodiazepines |
| US6403609B1 (en) | 1997-07-29 | 2002-06-11 | Alcon Manufacturing, Ltd. | Ophthalmic compositions containing galactomannan polymers and borate |
| CA2318920A1 (en) | 1998-01-29 | 1999-08-05 | James W. Young | Pharmaceutical uses of optically pure (-)-bupropion |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| CA2442066C (en) | 2001-04-02 | 2005-11-01 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| GB0204159D0 (en) | 2002-02-22 | 2002-04-10 | British Biotech Pharm | Metalloproteinase inhibitors |
| ATE489384T1 (de) * | 2002-05-06 | 2010-12-15 | Vertex Pharma | Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| DE602004023516D1 (de) | 2003-08-07 | 2009-11-19 | Allergan Inc | Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| AR046787A1 (es) * | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| WO2006133216A2 (en) | 2005-06-06 | 2006-12-14 | Smithkline Beecham Corporation | 4-substituted arylamine derivatives and their use in pharmaceutical compositions |
| US20090042926A1 (en) | 2005-12-20 | 2009-02-12 | Jason Imbriglio | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment |
| EP1999119A2 (en) | 2006-02-15 | 2008-12-10 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| SI2076501T1 (sl) | 2006-09-25 | 2016-05-31 | Ptc Therapeutics, Inc. | Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| EP2178531A4 (en) | 2007-07-02 | 2012-01-11 | Yu Ming | METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| CL2009000400A1 (es) | 2008-02-22 | 2010-09-10 | Irm Llc | Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras. |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
| US20120088747A1 (en) * | 2008-10-30 | 2012-04-12 | Saunders Jeffrey O | Sulfonamide containing compounds and uses thereof |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011137587A1 (en) | 2010-05-06 | 2011-11-10 | Hutchison Medipharma Limited | Cytokine inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012129564A2 (en) | 2011-03-24 | 2012-09-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Proteasome chymotrypsin-like inhibition using pi-1833 analogs |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| KR20140069235A (ko) | 2011-09-27 | 2014-06-09 | 노파르티스 아게 | 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| JP5808869B2 (ja) * | 2011-11-03 | 2015-11-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二環式ピペラジン化合物 |
| MX2014005289A (es) * | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de piperazina alquilados. |
| CA2853967A1 (en) * | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| EP2831108A1 (en) | 2012-03-29 | 2015-02-04 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| KR101947702B1 (ko) | 2012-10-04 | 2019-02-14 | 다나-파버 캔서 인스티튜트 인크. | 인간 단클론 항-pd-l1 항체 및 사용 방법 |
| ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
| EA030155B1 (ru) * | 2013-09-06 | 2018-06-29 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,2,4-оксадиазола в качестве иммуномодуляторов |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| WO2016073470A1 (en) | 2014-11-04 | 2016-05-12 | The University Of Kansas | Lkb1-ampk activators for therapeutic use in polycystic kidney disease |
| KR102708045B1 (ko) * | 2015-03-10 | 2024-09-23 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| BR112017019306A2 (pt) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores |
| CN107427476A (zh) | 2015-03-10 | 2017-12-01 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| EA201990997A1 (ru) | 2016-10-20 | 2019-08-30 | Ориджин Дискавери Текнолоджиз Лимитед | Двойные ингибиторы vista и путей pd-1 |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| JP7618445B2 (ja) | 2017-10-11 | 2025-01-21 | オーリジーン オンコロジー リミテッド | ３－置換１，２，４－オキサジアゾールの結晶形態 |
| CN111372584A (zh) | 2017-11-03 | 2020-07-03 | 奥瑞基尼探索技术有限公司 | Tim-3和pd-1途径的双重抑制剂 |
| EA202090749A1 (ru) | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
-
2016
- 2016-03-07 KR KR1020177025706A patent/KR102708045B1/ko active Active
- 2016-03-07 HR HRP20220258TT patent/HRP20220258T1/hr unknown
- 2016-03-07 LT LTEPPCT/IB2016/051266T patent/LT3267984T/lt unknown
- 2016-03-07 HU HUE16761169A patent/HUE058274T2/hu unknown
- 2016-03-07 AU AU2016230793A patent/AU2016230793B2/en active Active
- 2016-03-07 IL IL254040A patent/IL254040B2/en unknown
- 2016-03-07 NZ NZ734650A patent/NZ734650A/en unknown
- 2016-03-07 CN CN202111317930.6A patent/CN114159430B/zh active Active
- 2016-03-07 CN CN202111317986.1A patent/CN114213356A/zh active Pending
- 2016-03-07 SI SI201631482T patent/SI3267984T1/sl unknown
- 2016-03-07 MX MX2020003735A patent/MX389392B/es unknown
- 2016-03-07 CA CA2979137A patent/CA2979137C/en active Active
- 2016-03-07 PT PT167611698T patent/PT3267984T/pt unknown
- 2016-03-07 CU CU2017000119A patent/CU24509B1/es unknown
- 2016-03-07 DK DK16761169.8T patent/DK3267984T3/da active
- 2016-03-07 CA CA3220902A patent/CA3220902A1/en active Pending
- 2016-03-07 IL IL305546A patent/IL305546A/en unknown
- 2016-03-07 CN CN201680014744.6A patent/CN107427477B/zh active Active
- 2016-03-07 MY MYPI2017703073A patent/MY196130A/en unknown
- 2016-03-07 CN CN202111303250.9A patent/CN114044760A/zh active Pending
- 2016-03-07 EA EA201791626A patent/EA034708B1/ru unknown
- 2016-03-07 WO PCT/IB2016/051266 patent/WO2016142833A1/en not_active Ceased
- 2016-03-07 JP JP2017547558A patent/JP6815686B2/ja active Active
- 2016-03-07 SM SM20220163T patent/SMT202200163T1/it unknown
- 2016-03-07 SG SG10202108921VA patent/SG10202108921VA/en unknown
- 2016-03-07 PL PL16761169T patent/PL3267984T3/pl unknown
- 2016-03-07 ES ES16761169T patent/ES2907988T3/es active Active
- 2016-03-07 EP EP21209727.3A patent/EP4023645A1/en active Pending
- 2016-03-07 EP EP16761169.8A patent/EP3267984B1/en active Active
- 2016-03-07 MX MX2017011618A patent/MX384444B/es unknown
- 2016-03-07 SG SG11201706908PA patent/SG11201706908PA/en unknown
- 2016-03-07 KR KR1020247030801A patent/KR102894264B1/ko active Active
- 2016-03-07 US US15/556,800 patent/US10781189B2/en active Active
- 2016-03-07 RS RS20220194A patent/RS62960B1/sr unknown
-
2017
- 2017-08-11 PH PH12017501454A patent/PH12017501454A1/en unknown
-
2020
- 2020-07-29 JP JP2020128394A patent/JP6937090B2/ja active Active
- 2020-08-01 US US16/945,854 patent/US11465976B2/en active Active
-
2021
- 2021-06-22 AU AU2021204220A patent/AU2021204220B2/en active Active
- 2021-08-27 JP JP2021139182A patent/JP7325483B6/ja active Active
-
2022
- 2022-02-24 CY CY20221100154T patent/CY1125161T1/el unknown
- 2022-10-10 US US17/962,976 patent/US20230110077A1/en not_active Abandoned
-
2023
- 2023-08-01 JP JP2023125731A patent/JP7659015B2/ja active Active
-
2024
- 2024-01-15 AU AU2024200257A patent/AU2024200257A1/en active Pending
-
2025
- 2025-03-26 JP JP2025052596A patent/JP2025114536A/ja active Pending
- 2025-09-04 IL IL323188A patent/IL323188A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3267984T4 (pl) | Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory | |
| IL289511A (en) | Benzoxazole derivatives as immunomodulators | |
| IL288232A (en) | 1,7- naphthyridine as immunomodulators | |
| IL259406B (en) | Heterocyclic compounds as immunomodulators | |
| PL4212529T3 (pl) | Związki heterocykliczne jako immunomodulatory | |
| IL264092A (en) | 1, 3-dihydroxy-phenyl derivatives are useful as immunomodulators | |
| IL254046A0 (en) | Thiadiazole and 1,3,4-oxadiazole compounds for use as immunomodulators | |
| MA49859A (fr) | Immunomodulateurs macrocycliques | |
| IL254044A0 (en) | Thiadiazole compounds and 1,3,4-oxadiazole modified in position 3 for use as immunomodulators | |
| DK3472167T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
| HUE051659T2 (hu) | Makrociklusos peptidek, amelyek hasznosak immunmodulátorokként | |
| ME03003B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| LT3230281T (lt) | 1,3-tiazol-2-ilu pakeisti benzamidai | |
| DK3139769T3 (da) | Næringsrige sammensætninger | |
| EP3445262A4 (en) | TROCARS | |
| EP3385556A4 (en) | SHAFT COUPLING | |
| EA202092926A3 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| DK3138840T3 (da) | Thiadiazolidin-derivat som anti-enterovirus 71 | |
| EP3517639A4 (en) | CEMENTED SHAFT COMPONENT | |
| DE112017001982A5 (de) | Antriebsanordnung | |
| DE112017001454A5 (de) | Antriebsanordnung | |
| DE112014006555A5 (de) | Kommutierungsschaltung | |
| TH1901003875A (th) | อนุพันธ์เบนโซออกซาโซลในรูปของสารปรับภูมิคุ้มกัน | |
| TH1601001291A (th) | อนุพันธ์ 1,2,4-ออกซาไดอะโซลที่เป็นสารปรับภูมิคุ้มกัน | |
| TH1601001213A (th) | สารประกอบที่เป็นประโยชน์ในฐานะเป็นสารปรับภูมิคุ้มกัน |